FDA Assigns BTD and Receives BLA for RP1 Combo in Advanced Melanoma
Vusolimogene oderparepvec in combination with nivolumab has received breakthrough therapy designation from the FDA in advanced melanoma.
Vusolimogene oderparepvec in combination with nivolumab has received breakthrough therapy designation from the FDA in advanced melanoma.
This 30-minute live social event features two expert faculty members leading an interactive discussion focused on the care of patients with neurofibromatosis…
Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.
The International Association for the Study of Lung Cancer (IASLC) is the only global network dedicated to the study and eradication of lung cancer and…
Viral loads of human papillomavirus (HPV)16, HPV31, HPV33, HPV35, and HPV58 were significantly associated with the grade of cervical lesions. The viral load of specific…
LBL-024, a bispecific antibody targeting PD-L1 and 4-1BB, has received FDA orphan drug designation for neuroendocrine cancer treatment.
This cross-sectional study investigates if there are differences in the receipt of recurrence-focused treatment and overall survival in patients with pancreatic ductal adenocarcinoma recurrence who…
Elias Jabbour, MD, highlights the significance of obecabtagene autoleucel’s approval for patients with B-cell precursor ALL and data from the FELIX trial.
Saad Z. Usmani: Engaging discussions at this year’s Myeloma Meeting / cancer, Marivi Mateos, Memorial Sloan Kettering Cancer Center, Mohamad Mohty, Noopur
About OncoHealth OncoHealth is a leading digital health company dedicated to helping health plans, employers, providers, and patients navigate the physical, mental, and financial complexities…
The rising incidence and mortality of lung cancer among certain populations have resulted in a major health crisis worldwide. Despite comparatively less exposure to occupational…